bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Figure 5 from Molecular Clusters and Tumor-Immune Drivers of IgM Monoclonal Gammopathies
Authors: Mondello Patrizia , Paludo Jonas , Novak Joseph P. , Wenzl Kerstin , Yang Zhi-Zhang , Jalali Shahrzad , Krull Jordan E. , Braggio Esteban , Dasari Surendra , Manske Michelle K. , Abeykoon Jithma A. , Sarangi Vivekananda , Kapoor Prashant , Paulus Aneel , Reeder Craig B. , Ailawadhi Sikander , Chanan-Khan Asher A. , Kyle Robert A. , Gertz Morie A. , Novak Anne J. , Ansell Stephen M.
Published: April 2023

Supplementary Figure 5 A. Heat map of Spearman's correlation coefficients among paired proteins in the bone marrow (BM) supernatant and peripheral blood (PB) serum of 16 patients with WM (n=11) and IgM MGUS (n=5). Positive correlations are shown in red, whereas negative correlations are indicated in blue. B. Heat maps showing expression of (i) 12 proteins significantly different between C1 vs C2 plus C3, and (i) 74 proteins significantly different between C2 vs C1 plus C3 in the PB serum. The left bar shows correlation coefficients between BM and PB proteins. Gray squares indicate non significance.
Figure S1 from Oral IRAK-4 Inhibitor CA-4948 Is Blood-Brain Barrier Penetrant and Has Single-Agent Activity against CNS Lymphoma and Melanoma Brain Metastases
Authors: Von Roemeling Christina A. , Doonan Bently P. , Klippel Kelena , Schultz Daniel , Hoang-Minh Lan , Trivedi Vrunda , Li Chenglong , Russell Rylynn A. , Kanumuri Raju S. , Sharma Abhisheak , Tun Han W. , Mitchell Duane A.
Published: April 2023

Supplemental Figure 1. Myddosome signaling in normal human cerebral cortex.
Supplementary Table 2 from Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor–Positive (HR+)/HER2-Negative Metastatic Breast Cancer
Authors: Davis Andrew A. , Luo Jingqin , Zheng Tiantian , Dai Chao , Dong Xiaoxi , Tan Lu , Suresh Rama , Ademuyiwa Foluso O. , Rigden Caron , Rearden Timothy P. , Clifton Katherine , Weilbaecher Katherine , Frith Ashley , Tandra Pavan K. , Summa Tracy , Haas Brittney , Thomas Shana , Hernandez-Aya Leonel F. , Peterson Lindsay L. , Wang Xiaohong , Luo Shujun J. , Zhou Kemin , Du Pan , Jia Shidong , King Bonnie L. , Krishnamurthy Jairam , Ma Cynthia X.
Published: April 2023

Patient demographics.
Supplementary Methods S1 from Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor–Positive (HR+)/HER2-Negative Metastatic Breast Cancer
Authors: Davis Andrew A. , Luo Jingqin , Zheng Tiantian , Dai Chao , Dong Xiaoxi , Tan Lu , Suresh Rama , Ademuyiwa Foluso O. , Rigden Caron , Rearden Timothy P. , Clifton Katherine , Weilbaecher Katherine , Frith Ashley , Tandra Pavan K. , Summa Tracy , Haas Brittney , Thomas Shana , Hernandez-Aya Leonel F. , Peterson Lindsay L. , Wang Xiaohong , Luo Shujun J. , Zhou Kemin , Du Pan , Jia Shidong , King Bonnie L. , Krishnamurthy Jairam , Ma Cynthia X.
Published: April 2023

Supplementary Methods
Supplementary Figure S1 from Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases
Authors: Wilmott James S. , Tawbi Hussein , Engh Johnathan A. , Amankulor Nduka M. , Shivalingam Brindha , Banerjee Hiya , Vergara Ismael A. , Lee Hansol , Johansson Peter A. , Ferguson Peter M. , Saiag Philippe , Robert Caroline , Grob Jean-Jacques , Butterfield Lisa H. , Scolyer Richard A. , Kirkwood John M. , Long Georgina V. , Davies Michael A.
Published: April 2023

Gene expression of major signalling pathways and multiplex immunohistochemical comparison of markers between timepoints and tumor sites. A) Gene expression of related oncogenic signalling pathways between treatment timepoints and site, B) Estimated mean difference of proteins and pathways between biopsy categories (95% confidence interval for the estimated mean difference is depicted as a segment), C) Multiplex immunohistochemical staining for key intracellular signalling proteins, D) Changes in immune intratumoral immune cell densities between treatment timepoints and site, E and F) Multiplex immunohistochemical staining depicted marked decrease in immune cell densities EDT in PT4 (steroid treated). PRE, collected prior to treatment; EDT, collected early during treatment (i.e., after 10-14 days of dabrafenib). MBM, melanoma brain metastasis; ECM, extracranial metastasis. PT, patient.
Supplementary Table S6 from Prediction of Response to Lenvatinib Monotherapy for Unresectable Hepatocellular Carcinoma by Machine Learning Radiomics: A Multicenter Cohort Study
Authors: Bo Zhiyuan , Chen Bo , Zhao Zhengxiao , He Qikuan , Mao Yicheng , Yang Yunjun , Yao Fei , Yang Yi , Chen Ziyan , Yang Jinhuan , Yu Haitao , Ma Jun , Wu Lijun , Chen Kaiyu , Wang Luhui , Wang Mingxun , Shi Zhehao , Yao Xinfei , Dong Yulong , Shi Xintong , Shan Yunfeng , Yu Zhengping , Wang Yi , Chen Gang
Published: April 2023

Comparison of predictive value of 10 machine learning algorithms for predicting the response to lenvatinib in the training and external validation cohorts.
Supplementary Table S5 from Prediction of Response to Lenvatinib Monotherapy for Unresectable Hepatocellular Carcinoma by Machine Learning Radiomics: A Multicenter Cohort Study
Authors: Bo Zhiyuan , Chen Bo , Zhao Zhengxiao , He Qikuan , Mao Yicheng , Yang Yunjun , Yao Fei , Yang Yi , Chen Ziyan , Yang Jinhuan , Yu Haitao , Ma Jun , Wu Lijun , Chen Kaiyu , Wang Luhui , Wang Mingxun , Shi Zhehao , Yao Xinfei , Dong Yulong , Shi Xintong , Shan Yunfeng , Yu Zhengping , Wang Yi , Chen Gang
Published: April 2023

Baseline characteristics between two different radiomics-based subtypes for unresectable HCC treated with lenvatinib monotherapy.
Supplementary Table S4 from Beneficial Effects of Mifepristone Treatment in Patients with Breast Cancer Selected by the Progesterone Receptor Isoform Ratio: Results from the MIPRA Trial
Authors: Elía Andrés , Saldain Leo , Vanzulli Silvia I. , Helguero Luisa A. , Lamb Caroline A. , Fabris Victoria , Pataccini Gabriela , Martínez-Vazquez Paula , Burruchaga Javier , Caillet-Bois Ines , Spengler Eunice , Acosta Haab Gabriela , Liguori Marcos , Castets Alejandra , Lovisi Silvia , Abascal María F. , Novaro Virginia , Sánchez Jana , Muñoz Javier , Belizán José M. , Abba Martín C. , Gass Hugo , Rojas Paola , Lanari Claudia
Published: April 2023

RNA-Seq DEG and GSEA
Supplementary Materials S1 from BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma
Authors: Kurata Keiji , Samur Mehmet K. , Liow Priscilla , Wen Kenneth , Yamamoto Leona , Liu Jiye , Morelli Eugenio , Gulla Annamaria , Tai Yu-Tzu , Qi Jun , Hideshima Teru , Anderson Kenneth C.
Published: April 2023

Supplementary Materials
Supplementary Figure S2 from BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma
Authors: Kurata Keiji , Samur Mehmet K. , Liow Priscilla , Wen Kenneth , Yamamoto Leona , Liu Jiye , Morelli Eugenio , Gulla Annamaria , Tai Yu-Tzu , Qi Jun , Hideshima Teru , Anderson Kenneth C.
Published: April 2023

Ribosome biogenesis and translation signatures are upregulated in BRD9-depletion-sensitive MM cell lines.
Supplementary Figure S4 from Beneficial Effects of Mifepristone Treatment in Patients with Breast Cancer Selected by the Progesterone Receptor Isoform Ratio: Results from the MIPRA Trial
Authors: Elía Andrés , Saldain Leo , Vanzulli Silvia I. , Helguero Luisa A. , Lamb Caroline A. , Fabris Victoria , Pataccini Gabriela , Martínez-Vazquez Paula , Burruchaga Javier , Caillet-Bois Ines , Spengler Eunice , Acosta Haab Gabriela , Liguori Marcos , Castets Alejandra , Lovisi Silvia , Abascal María F. , Novaro Virginia , Sánchez Jana , Muñoz Javier , Belizán José M. , Abba Martín C. , Gass Hugo , Rojas Paola , Lanari Claudia
Published: April 2023

RNA-Seq and Proteomics analysis. A and B, Dot plot of relevant enriched pathways from GSEA results (Reactome and Hallmark databases) separating responsive (A) and unresponsive tumors (B). C, Immune cell deconvolution (xcell) in the different tumors analyzed by RNA-Seq. Plots with significant p values analyzed by Wilcoxon test and the T cell CD8+ plot are shown. D, Kegg diagram of the Cell cycle pathway, that may explain mifepristone therapeutics effects. A colored code was used: the first half of the box is colored according to the RNA-Seq data (8 tumors) and the last half of the box is colored according to the proteomic data (n=10 tumors; nuclear fraction).
Supplementary Figure S3 from Beneficial Effects of Mifepristone Treatment in Patients with Breast Cancer Selected by the Progesterone Receptor Isoform Ratio: Results from the MIPRA Trial
Authors: Elía Andrés , Saldain Leo , Vanzulli Silvia I. , Helguero Luisa A. , Lamb Caroline A. , Fabris Victoria , Pataccini Gabriela , Martínez-Vazquez Paula , Burruchaga Javier , Caillet-Bois Ines , Spengler Eunice , Acosta Haab Gabriela , Liguori Marcos , Castets Alejandra , Lovisi Silvia , Abascal María F. , Novaro Virginia , Sánchez Jana , Muñoz Javier , Belizán José M. , Abba Martín C. , Gass Hugo , Rojas Paola , Lanari Claudia
Published: April 2023

A, Library size before and after low count filtering. B, P-value histogram distribution observed in the differential expression analysis. C, Pairwise scatter plots of the first five principal components from the principal component analysis of RNA-Seq data.
Supplementary Table S3 from A Pilot Study of Intralesional Injection of Triamcinolone Acetonide for Desmoid Tumors: Two-Year Outcomes
Authors: Wilke Benjamin K. , Garner Hillary W. , Bestic Joseph M. , Chase Lori A. , Heckman Michael G. , Schoch Jennifer J. , Attia Steven
Published: April 2023

Comparison of desmoid tumor PRO information between baseline, 6-month, and 24-month follow-up.
Supplementary Figure S3 from Synthetic Lethal Interaction with BCL-XL Blockade Deepens Response to Cetuximab in Patient-Derived Models of Metastatic Colorectal Cancer
Authors: Leto Simonetta M. , Ferri Martina , Sassi Francesco , Zanella Eugenia R. , Cottino Francesca , Vurchio Valentina , Catalano Irene , Ferrero Alessandro , Zingaretti Caterina C. , Marchiò Caterina , Grassi Elena , Trusolino Livio , Bertotti Andrea
Published: April 2023

Correlations between transcript expression of pro/anti-apoptotic proteins and response to combination therapy withcetuximab and BH3 mimetics.
Figure S3 from Exposure-Response Analyses of Tremelimumab Monotherapy or in Combination with Durvalumab in Patients with Unresectable Hepatocellular Carcinoma
Authors: Song Xuyang , Kelley Robin Kate , Khan Anis A. , Standifer Nathan , Zhou Diansong , Lim KyoungSoo , Krishna Rajesh , Liu Lu , Wang Kun , McCoon Patricia , Negro Alejandra , He Philip , Gibbs Megan , Kurland John F. , Abou-Alfa Ghassan K.
Published: April 2023

Supplementary Figure S3. CFB of proliferating CD8+Ki67+ T cells vs predicted tremelimumab exposure (PD analysis population) in patients with lower and higher baseline CD8+Ki67+ T-cell counts
Figure S2 from Exposure-Response Analyses of Tremelimumab Monotherapy or in Combination with Durvalumab in Patients with Unresectable Hepatocellular Carcinoma
Authors: Song Xuyang , Kelley Robin Kate , Khan Anis A. , Standifer Nathan , Zhou Diansong , Lim KyoungSoo , Krishna Rajesh , Liu Lu , Wang Kun , McCoon Patricia , Negro Alejandra , He Philip , Gibbs Megan , Kurland John F. , Abou-Alfa Ghassan K.
Published: April 2023

Supplementary Figure S2. The effect of covariates, body weight, baseline albumin level, and combination therapy, on tremelimumab exposure metric Cmin1 (PK analysis population)
Figure S1 from Exposure-Response Analyses of Tremelimumab Monotherapy or in Combination with Durvalumab in Patients with Unresectable Hepatocellular Carcinoma
Authors: Song Xuyang , Kelley Robin Kate , Khan Anis A. , Standifer Nathan , Zhou Diansong , Lim KyoungSoo , Krishna Rajesh , Liu Lu , Wang Kun , McCoon Patricia , Negro Alejandra , He Philip , Gibbs Megan , Kurland John F. , Abou-Alfa Ghassan K.
Published: April 2023

Supplementary Figure S1. Flow diagram of patients included in the PK analysis, exposure-response analysis, and PD analysis datasets
Supplementary Table S4: Clinical trials of CD73 inhibitors from ENPP1 Immunobiology as a Therapeutic Target
Authors: Ruiz-Fernández de Córdoba Borja , Martínez-Monge Rafael , Lecanda Fernando
Published: April 2023

Clinical trials of CD73 inhibitors
Supplementary Figure S6 from Human Effectors of Acute and Chronic GVHD Overexpress CD83 and Predict Mortality
Authors: Holtan Shernan G. , Savid-Frontera Constanza , Walton Kelly , Eaton Anne A. , Demorest Connor , Hoeschen Andrea , Zhang Ling , Reid Kayla , Kurian Tony , Sayegh Zena , Julia Estefania , Maakaron Joseph , Bachanova Veronika , Jurdi Najla El , MacMillan Margaret L. , Weisdorf Daniel J. , Felices Martin , Miller Jeffrey S. , Blazar Bruce R. , Davila Marco L. , Betts Brian C.
Published: April 2023

Targeting CD83 in human AML
Supplementary Figure S3 from Human Effectors of Acute and Chronic GVHD Overexpress CD83 and Predict Mortality
Authors: Holtan Shernan G. , Savid-Frontera Constanza , Walton Kelly , Eaton Anne A. , Demorest Connor , Hoeschen Andrea , Zhang Ling , Reid Kayla , Kurian Tony , Sayegh Zena , Julia Estefania , Maakaron Joseph , Bachanova Veronika , Jurdi Najla El , MacMillan Margaret L. , Weisdorf Daniel J. , Felices Martin , Miller Jeffrey S. , Blazar Bruce R. , Davila Marco L. , Betts Brian C.
Published: April 2023

Clinical outcomes based on chronic GVHD or frequency of circulating CD83 B cells or Tfh
Supplementary Data TS1 from Tumor Dynamic Model-Based Decision Support for Phase Ib/II Combination Studies: A Retrospective Assessment Based on Resampling of the Phase III Study IMpower150
Authors: Bruno René , Marchand Mathilde , Yoshida Kenta , Chan Phyllis , Li Haocheng , Zou Wei , Mercier Francois , Chanu Pascal , Wu Benjamin , Lee Anthony , Li Chunze , Jin Jin Y. , Maitland Michael L. , Reck Martin , Socinski Mark A.
Published: April 2023

Supplementary Tables
Supplemental Figure 1 from Response to Neoadjuvant Targeted Therapy in Operable Head and Neck Cancer Confers Survival Benefit
Authors: Mascarella Marco A. , Olonisakin Tolani F. , Rumde Purva , Vendra Varun , Nance Melonie A. , Kim Seungwon , Kubik Mark W. , Sridharan Shaum S. , Ferris Robert L. , Fenton Moon J. , Clayburgh Daniel R. , Ohr James P. , Joyce Sonali C. , Sen Malabika , Herman James G. , Grandis Jennifer R. , Zandberg Dan P. , Duvvuri Umamaheswar
Published: April 2023

CONSORT diagram of patients included neoadjuvant targeted therapy trials
Supplementary Table S3. from Multi-Maintenance Olaparib Therapy in Relapsed, Germline BRCA1/2-Mutant High-Grade Serous Ovarian Cancer (MOLTO): A Phase II Trial
Authors: Morgan Robert D. , Clamp Andrew R. , White Daniel J. , Price Marcus , Burghel George J. , Ryder W. David J. , Mahmood Reem D. , Murphy Alexander D. , Hasan Jurjees , Mitchell Claire L. , Salih Zena , Wheeler Chelsey , Buckley Emma , Truelove Joanna , King Georgia , Ainaoui Yasmina , Bhaskar Sanjeev S. , Shaw Joseph , Evans D. Gareth R. , Kilerci Bedirhan , Pearce Simon P. , Brady Gerard , Dive Caroline , O'Connor James P.B. , Wallace Andrew J. , Rothwell Dominic G. , Edmondson Richard J. , Jayson Gordon C.
Published: April 2023

Liquid biopsy time points.
Supplementary Table S2. from Multi-Maintenance Olaparib Therapy in Relapsed, Germline BRCA1/2-Mutant High-Grade Serous Ovarian Cancer (MOLTO): A Phase II Trial
Authors: Morgan Robert D. , Clamp Andrew R. , White Daniel J. , Price Marcus , Burghel George J. , Ryder W. David J. , Mahmood Reem D. , Murphy Alexander D. , Hasan Jurjees , Mitchell Claire L. , Salih Zena , Wheeler Chelsey , Buckley Emma , Truelove Joanna , King Georgia , Ainaoui Yasmina , Bhaskar Sanjeev S. , Shaw Joseph , Evans D. Gareth R. , Kilerci Bedirhan , Pearce Simon P. , Brady Gerard , Dive Caroline , O'Connor James P.B. , Wallace Andrew J. , Rothwell Dominic G. , Edmondson Richard J. , Jayson Gordon C.
Published: April 2023

Progression-free survival according to functional homologous recombination repair and somatic copy-number alteration status.
Supplementary Table S9 from A Phase II Window of Opportunity Study of Neoadjuvant PD-L1 versus PD-L1 plus CTLA-4 Blockade for Patients with Malignant Pleural Mesothelioma
Authors: Lee Hyun-Sung , Jang Hee-Jin , Ramineni Maheshwari , Wang Daniel Y. , Ramos Daniela , Choi Jong Min , Splawn Taylor , Espinoza Monica , Almarez Michelle , Hosey Leandria , Jo Eunji , Hilsenbeck Susan , Amos Christopher I. , Ripley R. Taylor , Burt Bryan M.
Published: April 2023

Supplementary Table 9. CyTOF antibody panel for PBMC, BMMC, and tumor-infiltrating immune cells, relevant to Supplementary Figure 10.
Supplementary Figure S5. from Multi-Maintenance Olaparib Therapy in Relapsed, Germline BRCA1/2-Mutant High-Grade Serous Ovarian Cancer (MOLTO): A Phase II Trial
Authors: Morgan Robert D. , Clamp Andrew R. , White Daniel J. , Price Marcus , Burghel George J. , Ryder W. David J. , Mahmood Reem D. , Murphy Alexander D. , Hasan Jurjees , Mitchell Claire L. , Salih Zena , Wheeler Chelsey , Buckley Emma , Truelove Joanna , King Georgia , Ainaoui Yasmina , Bhaskar Sanjeev S. , Shaw Joseph , Evans D. Gareth R. , Kilerci Bedirhan , Pearce Simon P. , Brady Gerard , Dive Caroline , O'Connor James P.B. , Wallace Andrew J. , Rothwell Dominic G. , Edmondson Richard J. , Jayson Gordon C.
Published: April 2023

BRCA2 reversion mutation detected in cell-free circulating DNA from patient 16.
Supplementary Table S5 from A Phase II Window of Opportunity Study of Neoadjuvant PD-L1 versus PD-L1 plus CTLA-4 Blockade for Patients with Malignant Pleural Mesothelioma
Authors: Lee Hyun-Sung , Jang Hee-Jin , Ramineni Maheshwari , Wang Daniel Y. , Ramos Daniela , Choi Jong Min , Splawn Taylor , Espinoza Monica , Almarez Michelle , Hosey Leandria , Jo Eunji , Hilsenbeck Susan , Amos Christopher I. , Ripley R. Taylor , Burt Bryan M.
Published: April 2023

Supplementary Table 5. IMC antibody panel relevant to Figure 1 and Figure 3.
Supplementary Figure S2. from Multi-Maintenance Olaparib Therapy in Relapsed, Germline BRCA1/2-Mutant High-Grade Serous Ovarian Cancer (MOLTO): A Phase II Trial
Authors: Morgan Robert D. , Clamp Andrew R. , White Daniel J. , Price Marcus , Burghel George J. , Ryder W. David J. , Mahmood Reem D. , Murphy Alexander D. , Hasan Jurjees , Mitchell Claire L. , Salih Zena , Wheeler Chelsey , Buckley Emma , Truelove Joanna , King Georgia , Ainaoui Yasmina , Bhaskar Sanjeev S. , Shaw Joseph , Evans D. Gareth R. , Kilerci Bedirhan , Pearce Simon P. , Brady Gerard , Dive Caroline , O'Connor James P.B. , Wallace Andrew J. , Rothwell Dominic G. , Edmondson Richard J. , Jayson Gordon C.
Published: April 2023

Functional homologous recombination repair.
Supplementary Figure S8 from A Phase II Window of Opportunity Study of Neoadjuvant PD-L1 versus PD-L1 plus CTLA-4 Blockade for Patients with Malignant Pleural Mesothelioma
Authors: Lee Hyun-Sung , Jang Hee-Jin , Ramineni Maheshwari , Wang Daniel Y. , Ramos Daniela , Choi Jong Min , Splawn Taylor , Espinoza Monica , Almarez Michelle , Hosey Leandria , Jo Eunji , Hilsenbeck Susan , Amos Christopher I. , Ripley R. Taylor , Burt Bryan M.
Published: April 2023

Supplementary Figure 8. Phenotyping of circulating CD8 and CD4 T cells in MPM patients that
received neoadjuvant ICB
Supplementary Figure S6 from A Phase II Window of Opportunity Study of Neoadjuvant PD-L1 versus PD-L1 plus CTLA-4 Blockade for Patients with Malignant Pleural Mesothelioma
Authors: Lee Hyun-Sung , Jang Hee-Jin , Ramineni Maheshwari , Wang Daniel Y. , Ramos Daniela , Choi Jong Min , Splawn Taylor , Espinoza Monica , Almarez Michelle , Hosey Leandria , Jo Eunji , Hilsenbeck Susan , Amos Christopher I. , Ripley R. Taylor , Burt Bryan M.
Published: April 2023

Supplementary Figure 6. Germinal center containing Ki67(+) B cells and CD68(+) fDC-like cell
meshwork in mature tertiary lymphoid structure.
Supplementary Figure S5 from A Phase II Window of Opportunity Study of Neoadjuvant PD-L1 versus PD-L1 plus CTLA-4 Blockade for Patients with Malignant Pleural Mesothelioma
Authors: Lee Hyun-Sung , Jang Hee-Jin , Ramineni Maheshwari , Wang Daniel Y. , Ramos Daniela , Choi Jong Min , Splawn Taylor , Espinoza Monica , Almarez Michelle , Hosey Leandria , Jo Eunji , Hilsenbeck Susan , Amos Christopher I. , Ripley R. Taylor , Burt Bryan M.
Published: April 2023

Supplementary Figure 5. Overall survival of historical MPM cohorts
Supplementary Figure S3 from A Phase II Window of Opportunity Study of Neoadjuvant PD-L1 versus PD-L1 plus CTLA-4 Blockade for Patients with Malignant Pleural Mesothelioma
Authors: Lee Hyun-Sung , Jang Hee-Jin , Ramineni Maheshwari , Wang Daniel Y. , Ramos Daniela , Choi Jong Min , Splawn Taylor , Espinoza Monica , Almarez Michelle , Hosey Leandria , Jo Eunji , Hilsenbeck Susan , Amos Christopher I. , Ripley R. Taylor , Burt Bryan M.
Published: April 2023

Supplementary Figure 3. Expression of pan-cytokeratin in sarcomatoid malignant pleural
mesothelioma.
Supplementary Figure S2 from A Phase II Window of Opportunity Study of Neoadjuvant PD-L1 versus PD-L1 plus CTLA-4 Blockade for Patients with Malignant Pleural Mesothelioma
Authors: Lee Hyun-Sung , Jang Hee-Jin , Ramineni Maheshwari , Wang Daniel Y. , Ramos Daniela , Choi Jong Min , Splawn Taylor , Espinoza Monica , Almarez Michelle , Hosey Leandria , Jo Eunji , Hilsenbeck Susan , Amos Christopher I. , Ripley R. Taylor , Burt Bryan M.
Published: April 2023

Supplementary Figure 2. Analysis scheme for imaging mass cytometry (IMC).
Supplementary Figure S11 from A Phase II Window of Opportunity Study of Neoadjuvant PD-L1 versus PD-L1 plus CTLA-4 Blockade for Patients with Malignant Pleural Mesothelioma
Authors: Lee Hyun-Sung , Jang Hee-Jin , Ramineni Maheshwari , Wang Daniel Y. , Ramos Daniela , Choi Jong Min , Splawn Taylor , Espinoza Monica , Almarez Michelle , Hosey Leandria , Jo Eunji , Hilsenbeck Susan , Amos Christopher I. , Ripley R. Taylor , Burt Bryan M.
Published: April 2023

Supplementary Figure 11. Schematic illustration of the de novo anti-tumor immune response to ICB that occurs in the peripheral immune system.
Supplementary Table S2 from Molecular Subtypes of Head and Neck Cancer in Patients of African Ancestry
Authors: Mezghani Nadia , Yao Alexandria , Vasilyeva Daria , Kaplan Nicole , Shackelford Austin , Yoon Angela , Phillipone Elizabeth , Dubey Sunil , Schwartz Gary K. , Taylor Alison M. , Momen-Heravi Fatemeh
Published: April 2023

HNC patient cohort clinical data by race
Supplementary Figure S3 from Molecular Subtypes of Head and Neck Cancer in Patients of African Ancestry
Authors: Mezghani Nadia , Yao Alexandria , Vasilyeva Daria , Kaplan Nicole , Shackelford Austin , Yoon Angela , Phillipone Elizabeth , Dubey Sunil , Schwartz Gary K. , Taylor Alison M. , Momen-Heravi Fatemeh
Published: April 2023

Oropharyngeal HNC subtype mutations and copy number alterations by race
Supplementary Tables S1-2 from Elucidating the Genetic Landscape of Oral Leukoplakia to Predict Malignant Transformation
Authors: Wils Leon J. , Poell Jos B. , Brink Arjen , Evren Ilkay , Brouns Elisabeth R. , de Visscher Jan G.A.M. , Bloemena Elisabeth , Brakenhoff Ruud H.
Published: April 2023

Supplementary Table S1: Per sample sequencing characteristics; Supplementary Table S2: Co-occurrence rates and odds ratios for presence of dysplasia and investigated genomic markers.
Supplementary Table S2 from Functional Homologous Recombination Assay on FFPE Specimens of Advanced High-Grade Serous Ovarian Cancer Predicts Clinical Outcomes
Authors: Pikkusaari Sanna , Tumiati Manuela , Virtanen Anni , Oikkonen Jaana , Li Yilin , Perez-Villatoro Fernando , Muranen Taru , Salko Matilda , Huhtinen Kaisa , Kanerva Anna , Koskela Heidi , Tapper Johanna , Koivisto-Korander Riitta , Joutsiniemi Titta , Haltia Ulla-Maija , Lassus Heini , Hautaniemi Sampsa , Färkkilä Anniina , Hynninen Johanna , Hietanen Sakari , Carpén Olli , Kauppi Liisa
Published: April 2023

Tumor percentages estimated from H&E images and comparison between HR, ovaHRDScar and Telli2016 status.
Supplementary Figure S7 from Functional Homologous Recombination Assay on FFPE Specimens of Advanced High-Grade Serous Ovarian Cancer Predicts Clinical Outcomes
Authors: Pikkusaari Sanna , Tumiati Manuela , Virtanen Anni , Oikkonen Jaana , Li Yilin , Perez-Villatoro Fernando , Muranen Taru , Salko Matilda , Huhtinen Kaisa , Kanerva Anna , Koskela Heidi , Tapper Johanna , Koivisto-Korander Riitta , Joutsiniemi Titta , Haltia Ulla-Maija , Lassus Heini , Hautaniemi Sampsa , Färkkilä Anniina , Hynninen Johanna , Hietanen Sakari , Carpén Olli , Kauppi Liisa
Published: April 2023

Comparison of different fHR score cut-off values.
Supplementary Figure S6 from Functional Homologous Recombination Assay on FFPE Specimens of Advanced High-Grade Serous Ovarian Cancer Predicts Clinical Outcomes
Authors: Pikkusaari Sanna , Tumiati Manuela , Virtanen Anni , Oikkonen Jaana , Li Yilin , Perez-Villatoro Fernando , Muranen Taru , Salko Matilda , Huhtinen Kaisa , Kanerva Anna , Koskela Heidi , Tapper Johanna , Koivisto-Korander Riitta , Joutsiniemi Titta , Haltia Ulla-Maija , Lassus Heini , Hautaniemi Sampsa , Färkkilä Anniina , Hynninen Johanna , Hietanen Sakari , Carpén Olli , Kauppi Liisa
Published: April 2023

Comparison of surgery outcome between fHRD and fHRP groups.
Supplementary Figure S4 from Functional Homologous Recombination Assay on FFPE Specimens of Advanced High-Grade Serous Ovarian Cancer Predicts Clinical Outcomes
Authors: Pikkusaari Sanna , Tumiati Manuela , Virtanen Anni , Oikkonen Jaana , Li Yilin , Perez-Villatoro Fernando , Muranen Taru , Salko Matilda , Huhtinen Kaisa , Kanerva Anna , Koskela Heidi , Tapper Johanna , Koivisto-Korander Riitta , Joutsiniemi Titta , Haltia Ulla-Maija , Lassus Heini , Hautaniemi Sampsa , Färkkilä Anniina , Hynninen Johanna , Hietanen Sakari , Carpén Olli , Kauppi Liisa
Published: April 2023

Comparisons of fHR scores obtained from different anatomical locations.
Supplementary Figure S3 from Functional Homologous Recombination Assay on FFPE Specimens of Advanced High-Grade Serous Ovarian Cancer Predicts Clinical Outcomes
Authors: Pikkusaari Sanna , Tumiati Manuela , Virtanen Anni , Oikkonen Jaana , Li Yilin , Perez-Villatoro Fernando , Muranen Taru , Salko Matilda , Huhtinen Kaisa , Kanerva Anna , Koskela Heidi , Tapper Johanna , Koivisto-Korander Riitta , Joutsiniemi Titta , Haltia Ulla-Maija , Lassus Heini , Hautaniemi Sampsa , Färkkilä Anniina , Hynninen Johanna , Hietanen Sakari , Carpén Olli , Kauppi Liisa
Published: April 2023

Binned distributions of fHR scores in the discovery cohorts.
Supplementary Figure S12 from Elucidating the Genetic Landscape of Oral Leukoplakia to Predict Malignant Transformation
Authors: Wils Leon J. , Poell Jos B. , Brink Arjen , Evren Ilkay , Brouns Elisabeth R. , de Visscher Jan G.A.M. , Bloemena Elisabeth , Brakenhoff Ruud H.
Published: April 2023

Forest plot containing all markers included in the final prediction model after step-wise selection for all oral leukoplakias with presence of dysplasia in 63 OL samples. Each row represents one variable. The first column shows the assessed marker. The second column shows the hazard ratio with the 95% confidence interval. The third column is a visual representation of the hazard ratio and the 95% confidence interval. The final column is the adjusted P-value for each of the investigated variables. AIC = Akaike information criterion.
Supplementary Figure S11 from Elucidating the Genetic Landscape of Oral Leukoplakia to Predict Malignant Transformation
Authors: Wils Leon J. , Poell Jos B. , Brink Arjen , Evren Ilkay , Brouns Elisabeth R. , de Visscher Jan G.A.M. , Bloemena Elisabeth , Brakenhoff Ruud H.
Published: April 2023

Forest plot containing all markers including presence of dysplasia, clinical and genomic markers in 89 OL samples. Each row represents one variable. The first column shows the assessed marker. The second column shows the hazard ratio with the 95% confidence interval. The third column is a visual representation of the hazard ratio and the 95% confidence interval. The final column is the adjusted P-value for each of the investigated variables. CNAs = copy number aberrations. AIC = Akaike information criterion.
Supplemental Figure S3 from Favorable Activity and Safety Profile of Memory-Enriched CD19-Targeted Chimeric Antigen Receptor T-Cell Therapy in Adults with High-Risk Relapsed/Refractory ALL
Authors: Aldoss Ibrahim , Khaled Samer K. , Wang Xiuli , Palmer Joycelynne , Wang Yan , Wagner Jamie R. , Clark Mary C. , Simpson Jennifer , Paul Jinny , Vyas Vibhuti , Chien Sheng-Hsuan , Stein Anthony , Pullarkat Vinod , Salhotra Amandeep , Al Malki Monzr M. , Aribi Ahmed , Sandhu Karamjeet , Thomas Sandra H. , Budde Lihua E. , Marcucci Guido , Brown Christine E. , Forman Stephen J.
Published: April 2023

T cell subset analysis pre and post CAR T cell manufacturing
Supplemental Figure S2 from Favorable Activity and Safety Profile of Memory-Enriched CD19-Targeted Chimeric Antigen Receptor T-Cell Therapy in Adults with High-Risk Relapsed/Refractory ALL
Authors: Aldoss Ibrahim , Khaled Samer K. , Wang Xiuli , Palmer Joycelynne , Wang Yan , Wagner Jamie R. , Clark Mary C. , Simpson Jennifer , Paul Jinny , Vyas Vibhuti , Chien Sheng-Hsuan , Stein Anthony , Pullarkat Vinod , Salhotra Amandeep , Al Malki Monzr M. , Aribi Ahmed , Sandhu Karamjeet , Thomas Sandra H. , Budde Lihua E. , Marcucci Guido , Brown Christine E. , Forman Stephen J.
Published: April 2023

Persistence of Tcm-derived CD19-CAR T cells
Figure S7 from LAMC2 Regulates Key Transcriptional and Targetable Effectors to Support Pancreatic Cancer Growth
Authors: Erice Oihane , Narayanan Shruthi , Feliu Iker , Entrialgo-Cadierno Rodrigo , Malinova Antonia , Vicentini Caterina , Guruceaga Elizabeth , Delfino Pietro , Trajkovic-Arsic Marija , Moreno Haritz , Valencia Karmele , Blanco Ester , Macaya Irati , Öhlund Daniel , Khatri Purvesh , Lecanda Fernando , Scarpa Aldo , Siveke Jens T. , Corbo Vincenzo , Ponz-Sarvise Mariano , Vicent Silve
Published: April 2023

Suppl. Figure 7. A. KRAS, TP53, SMAD4 genetic alteration in the 2 PDO characterized by DNA sequencing.
Supplemental Figure S1 from Favorable Activity and Safety Profile of Memory-Enriched CD19-Targeted Chimeric Antigen Receptor T-Cell Therapy in Adults with High-Risk Relapsed/Refractory ALL
Authors: Aldoss Ibrahim , Khaled Samer K. , Wang Xiuli , Palmer Joycelynne , Wang Yan , Wagner Jamie R. , Clark Mary C. , Simpson Jennifer , Paul Jinny , Vyas Vibhuti , Chien Sheng-Hsuan , Stein Anthony , Pullarkat Vinod , Salhotra Amandeep , Al Malki Monzr M. , Aribi Ahmed , Sandhu Karamjeet , Thomas Sandra H. , Budde Lihua E. , Marcucci Guido , Brown Christine E. , Forman Stephen J.
Published: April 2023

Manufacturing schema for the clinical trial
Figure S1 from LAMC2 Regulates Key Transcriptional and Targetable Effectors to Support Pancreatic Cancer Growth
Authors: Erice Oihane , Narayanan Shruthi , Feliu Iker , Entrialgo-Cadierno Rodrigo , Malinova Antonia , Vicentini Caterina , Guruceaga Elizabeth , Delfino Pietro , Trajkovic-Arsic Marija , Moreno Haritz , Valencia Karmele , Blanco Ester , Macaya Irati , Öhlund Daniel , Khatri Purvesh , Lecanda Fernando , Scarpa Aldo , Siveke Jens T. , Corbo Vincenzo , Ponz-Sarvise Mariano , Vicent Silve
Published: April 2023

Suppl. Figure 1. A. Association analysis of LAMC2 expression with clinical variables using quartile 1 of H score (23.2) as cut-off. B. Correlation of LAMC2 expression and tumor volume in a tissue array of 119 PDAC samples. C and D. Survival analysis stratified by LAMC2 expression from ICGC and TCGA datasets.
Supplementary Figure S4 from Influence of Genomic Landscape on Cancer Immunotherapy for Newly Diagnosed Ovarian Cancer: Biomarker Analyses from the IMagyn050 Randomized Clinical Trial
Authors: Landen Charles N. , Molinero Luciana , Hamidi Habib , Sehouli Jalid , Miller Austin , Moore Kathleen N. , Taskiran Cagatay , Bookman Michael , Lindemann Kristina , Anderson Charles , Berger Regina , Myers Tashanna , Beiner Mario , Reid Thomas , Van Nieuwenhuysen Els , Green Andrew , Okamoto Aikou , Aghajanian Carol , Thaker Premal H. , Blank Stephanie V. , Khor Victor K. , Chang Ching-Wei , Lin Yvonne G. , Pignata Sandro
Published: April 2023

PFS by treatment arm according to TMB status (stratified by treatment approach, disease stage, and ECOG PS). A, TMB-low population. B, TMB-high population. CPB, paclitaxel, carboplatin, and bevacizumab.
Supplementary Figure S2 from Influence of Genomic Landscape on Cancer Immunotherapy for Newly Diagnosed Ovarian Cancer: Biomarker Analyses from the IMagyn050 Randomized Clinical Trial
Authors: Landen Charles N. , Molinero Luciana , Hamidi Habib , Sehouli Jalid , Miller Austin , Moore Kathleen N. , Taskiran Cagatay , Bookman Michael , Lindemann Kristina , Anderson Charles , Berger Regina , Myers Tashanna , Beiner Mario , Reid Thomas , Van Nieuwenhuysen Els , Green Andrew , Okamoto Aikou , Aghajanian Carol , Thaker Premal H. , Blank Stephanie V. , Khor Victor K. , Chang Ching-Wei , Lin Yvonne G. , Pignata Sandro
Published: April 2023

Mutations in A, BRCA1 but not in B, BRCA2, are associated with PD-L1-positive tumors.
Supplementary fig 4 from Dynamic Mutational Landscape of Cerebrospinal Fluid Circulating Tumor DNA and Predictors of Survival after Proton Craniospinal Irradiation for Leptomeningeal Metastases
Authors: Wijetunga N. Ari , Goglia Alexander G. , Weinhold Nils , Berger Michael F. , Cislo Michael , Higginson Daniel S. , Chabot Kiana , Osman Ahmed M. , Schaff Lauren , Pentsova Elena , Miller Alexandra M. , Powell Simon N. , Boire Adrienne , Yang Jonathan T.
Published: April 2023

Supplemental Figure 4. The distribution of clonal and subclonal alterations in CSF ctDNA pre and post-pCSI.
Supplementary Figure 6 from ALK Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
Authors: Blandin Anne-Florence , Giglio Ross , Graham Maya Srikanth , Garcia Guadalupe , Malinowski Seth , Woods Jared K. , Ramkissoon Shakti , Ramkissoon Lori , Dubois Frank , Schoolcraft Kathleen , Tsai Jessica , Wang Dayle , Jones Robert , Vogelzang Jayne , Pelton Kristine , Becker Sarah , Watkinson Fiona , Sinai Claire , Cohen Elizabeth F. , Booker Matthew A. , Tolstorukov Michael Y. , Haemels Veerle , Goumnerova Liliana , Wright Karen , Kieran Mark , Fehnel Katie , Reardon David , Tauziede-Espariat Arnault , Lulla Rishi , Carcamo Benjamin , Chaleff Stanley , Charest Alain , De Smet Frederik , Ligon Azra H. , Dubuc Adrian , Pages Melanie , Varlet Pascale , Wen Patrick Y. , Alexander Brian M. , Chi Susan , Alexandrescu Sanda , Kittler Ralf , Bachoo Robert , Bandopadhayay Pratiti , Beroukhim Rameen , Ligon Keith L.
Published: April 2023

Supplementary Figure 6: Single cell RNA sequencing comparison of ALK expression and other infant/pediatric glioma kinase drivers in developing human and mouse brain. A. 2D representation of human brain cell subtypes (48 samples) during cortex development using a single cell RNA-seq atlas (http://cells.ucsc.edu/?ds=cortex-dev) shows that ALK positive cells make up less than 1% of all cells in the dataset and aren't localized within a specific cluster.B. Cluster-level summary of the human scRNA dataset shows that ALK expression (TPM) is decreased compared to EGFR, NTRK2, and NTRK3, and ALK positive cells make up a much lower percentage of each cluster compared to those 3 genes.C. 2D representation of developmental mouse forebrain (E12.5 – P6) in a single cell RNA-seq atlas (http://cc-shiny-01.functionalgenomics.ca/braindex/clusters) shows similar results as seen in the human scRNA Nowakowski dataset.D. Cluster-level summary of the mouse scRNA dataset corroborates results seen in the Nowkowski scRNA dataset; that Alk expression (log-normalized) is decreased, and less prevalent than EGFR, NTRK2, and NTRK3.E. 2D representation of RNA sequencing data for NTRK1-3 genes in the Nowakowski developing human cortex dataset. Compared to ALK expression, the NTRK genes have increased expression levels, increased prevalence in the dataset, and show increased localization to specific cluster.F. Similar to (E), the 2D representation of Ntrk genes in the developing mouse scRNA dataset shows increased expression and prevalence compared to Alk.
Supplementary Table S2 from Loss of CDKN2A Cooperates with WWTR1(TAZ)–CAMTA1 Gene Fusion to Promote Tumor Progression in Epithelioid Hemangioendothelioma
Authors: Seavey Caleb N. , Hallett Andrea , Li Shuo , Che Kepeng , Pobbati Ajaybabu V. , Ma Shuang , Burtscher Ashley , Kanai Ryan , Lamar John M. , Rubin Brian P.
Published: April 2023

Supplemental Table 2. Primer sequences for genotyping, qualitative reverse transcriptase-PCR, and oligonucleotides for cloning.
Supplementary Data S1 from Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics
Authors: Lozano-Rabella Maria , Garcia-Garijo Andrea , Palomero Jara , Yuste-Estevanez Anna , Erhard Florian , Farriol-Duran Roc , Martín-Liberal Juan , Ochoa-de-Olza Maria , Matos Ignacio , Gartner Jared J. , Ghosh Michael , Canals Francesc , Vidal August , Piulats Josep Maria , Matías-Guiu Xavier , Brana Irene , Muñoz-Couselo Eva , Garralda Elena , Schlosser Andreas , Gros Alena
Published: April 2023

Includes a large list of all the peptides and details of the HLA-I ligands identified at <=0.01 FDR and >=30 ALC score
Supplementary Tables S1-7 from CEACAM1 Marks Highly Suppressive Intratumoral Regulatory T Cells for Targeted Depletion Therapy
Authors: Jeon Seung Hyuck , Kang Minyong , Jeon Minwoo , Chung Youseung , Kim A Reum , Lee Yong Joon , Kim Eui-Soon , Nam Heejin , Park Junsik , Lee Jung-Yun , Shin Eui-Cheol , Seo Seong Il , Park Su-Hyung
Published: April 2023

Supplementary Tables S1-7
Supplementary Figures S1-11 from CEACAM1 Marks Highly Suppressive Intratumoral Regulatory T Cells for Targeted Depletion Therapy
Authors: Jeon Seung Hyuck , Kang Minyong , Jeon Minwoo , Chung Youseung , Kim A Reum , Lee Yong Joon , Kim Eui-Soon , Nam Heejin , Park Junsik , Lee Jung-Yun , Shin Eui-Cheol , Seo Seong Il , Park Su-Hyung
Published: April 2023

Supplementary Figures S1-11
Supplementary Table S2 from Survival Outcomes, Digital TILs, and On-treatment PET/CT During Neoadjuvant Therapy for HER2-positive Breast Cancer: Results from the Randomized PREDIX HER2 Trial
Authors: Matikas Alexios , Johansson Hemming , Grybäck Per , Bjöhle Judith , Acs Balazs , Boyaci Ceren , Lekberg Tobias , Fredholm Hanna , Elinder Ellinor , Margolin Sara , Isaksson-Friman Erika , Bosch Ana , Lindman Henrik , Adra Jamila , Andersson Anne , Agartz Susanne , Hellström Mats , Zerdes Ioannis , Hartman Johan , Bergh Jonas , Hatschek Thomas , Foukakis Theodoros
Published: April 2023

Supplementary Table S2. Distribution of clinical and pathologic characteristics according to baseline tumor infiltrating lymphocytes (median value as cut-off)
Supplementary Movie S1 from Anticoagulants Enhance Molecular and Cellular Immunotherapy of Cancer by Improving Tumor Microcirculation Structure and Function and Redistributing Tumor Infiltrates
Authors: Wei Fang , Su Yuling , Quan Yibo , Li Xiaojia , Zou Qi , Zhang Liuxi , Li Shu , Jiang Mengmeng , Lin Guohuan , Liang Ping , He Jie , Xie Keping
Published: April 2023

Supplementary Movie S1. IVIM in vivo imaging was used to observe that heparin promoted the infiltration of transferred CD8+ T cells into Panc02 orthotopic tumors. The video corresponded to the experiment shown in Figure 6B. Representative images at 6h of CD8+ T adoptive transfer group were shown in Figure 6B (Blue, angiography Evans Blue; Green, CFSE-CD8+ T cells).
Supplementary Figures S1-S11 from Anticoagulants Enhance Molecular and Cellular Immunotherapy of Cancer by Improving Tumor Microcirculation Structure and Function and Redistributing Tumor Infiltrates
Authors: Wei Fang , Su Yuling , Quan Yibo , Li Xiaojia , Zou Qi , Zhang Liuxi , Li Shu , Jiang Mengmeng , Lin Guohuan , Liang Ping , He Jie , Xie Keping
Published: April 2023

Supplementary Figure S1. Enhanced Therapeutic Activity of Combined Use ofAdaptive Lymphocyte Transfer and Anti-coagulation in colorectal cancerSupplementary Figure S2. Lower amount of CD8 and CD4 infiltration in Panc02 and CT26 tumor models and higher amount of CD8 and CD4 infiltration in MC38 tumor modelSupplementary Figure S3. HeparinTreatment Neither Directly Killed nor Activated Lymphocytes to Kill Tumor CellsSupplementary Figure S4. Decreased Infiltration of FOXP3+ Treg Cells in Tumor Lesions After Heparin TreatmentSupplementary Figure S5. Increased iNOS+ Macrophages but Reduced CD206+ Macrophages in Panc02 Tumor Lesions after Heparin TreatmentSupplementary Figure S6. Increased iNOS+ Macrophages but Reduced CD206+ Macrophages in MC38 and CT26 Tumor Lesions after Heparin TreatmentSupplementary Figure S7. Heparin Treatment Increased BSA Penetration in Panc02 TumorsSupplementary Figure S8. Heparin Treatment Decreased Tumor Angiogenesis and Normalized the Remaining Tumor Blood Vessels Function of DynamicsSupplementary Figure S9. Heparin Treatment Decreased Tumor Angiogenesis, Normalized the Remaining Tumor Blood Vessels, and Accumulated CD8+ T Cells Infiltration around the Normalizing Tumor VascularSupplementary Figure S10. Decreased FasL expression on tumor vesselendothelial cells in Panc02 Tumor Lesions after Heparin TreatmentSupplementary Figure S11. Decreased fibrotic states in Panc02 Tumor Lesions after Heparin Treatment
Data from Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell Lymphoma
Authors: Westin Jason R. , Locke Frederick L. , Dickinson Michael , Ghobadi Armin , Elsawy Mahmoud , van Meerten Tom , Miklos David B. , Ulrickson Matthew L. , Perales Miguel-Angel , Farooq Umar , Wannesson Luciano , Leslie Lori , Kersten Marie José , Jacobson Caron A. , Pagel John M. , Wulf Gerald , Johnston Patrick , Rapoport Aaron P. , Du Linqiu , Vardhanabhuti Saran , Filosto Simone , Shah Jina , Snider Julia T. , Cheng Paul , To Christina , Oluwole Olalekan O. , Sureda Anna
Published: April 2023

AbstractPurpose:
Older patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) may be considered ineligible for curative-intent therapy including high-dose chemotherapy with autologous stem-cell transplantation (HDT-ASCT). Here, we report outcomes of a preplanned subgroup analysis of patients ≥65 years in ZUMA-7.
Patients and Methods:
Patients with LBCL refractory to or relapsed ≤12 months after first-line chemoimmunotherapy were randomized 1:1 to axicabtagene ciloleucel [axi-cel; autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy] or standard of care (SOC; 2–3 cycles of chemoimmunotherapy followed by HDT-ASCT). The primary endpoint was event-free survival (EFS). Secondary endpoints included safety and patient-reported outcomes (PROs).
Results:
Fifty-one and 58 patients aged ≥65 years were randomized to axi-cel and SOC, respectively. Median EFS was greater with axi-cel versus SOC (21.5 vs. 2.5 months; median follow-up: 24.3 months; HR, 0.276; descriptive P < 0.0001). Objective response rate was higher with axi-cel versus SOC (88% vs. 52%; OR, 8.81; descriptive P < 0.0001; complete response rate: 75% vs. 33%). Grade ≥3 adverse events occurred in 94% of axi-cel and 82% of SOC patients. No grade 5 cytokine release syndrome or neurologic events occurred. In the quality-of-life analysis, the mean change in PRO scores from baseline at days 100 and 150 favored axi-cel for EORTC QLQ-C30 Global Health, Physical Functioning, and EQ-5D-5L visual analog scale (descriptive P < 0.05). CAR T-cell expansion and baseline serum inflammatory profile were comparable in patients ≥65 and <65 years.
Conclusions:
Axi-cel is an effective second-line curative-intent therapy with a manageable safety profile and improved PROs for patients ≥65 years with R/R LBCL.
Data from Silencing of Transforming Growth Factor-β1 In situ by RNA Interference for Breast Cancer: Implications for Proliferation and Migration In vitro and Metastasis In vivo
Authors: Moore Lakisha D. , Isayeva Tatyana , Siegal Gene P. , Ponnazhagan Selvarangan
Published: April 2023

Abstract
Purpose: Overexpression of transforming growth factor (TGF)-β has been implicated in promoting immune suppression, tumor angiogenesis, tumor cell migration, and invasion in many cancers, including carcinoma of the breast. Thus, targeted down-regulation of TGF-β1 expression in breast cancer in situ and determination of its implications would provide new treatment approaches for disease management.

Experimental Design: Small interfering RNA constructs targeting TGF-β1 were validated and used to develop clonal derivatives of the metastatic breast cancer cell line MDA-MB-435. The cells were used in several in vitro analyses, including migration, invasion, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, apoptosis, and signaling assays. A wound-healing assay was used to determine migration of the cells in culture and a Boyden chamber transwell assay was used for invasion. Further, the clones were used in an in vivo mouse model for the kinetics of tumor growth and gene expression in the primary site and in lungs upon metastasis.

Results: Inhibition of TGF-β1 expression in MDA-MB-435 cells showed a 35% decrease in migration and a 55% decrease in invasion in vitro, with a 50% increase in proliferation and no effect on apoptosis. In vivo analysis indicated a 90% decrease in the number of mice bearing macroscopic lung metastases; however, the primary tumors did not show any difference in the growth kinetics when compared with the parental MDA-MB-435 cells. Analysis of TGF-β signaling pathways in the clonal derivatives showed a decrease in Smad2 activation and an increase in AKT and extracellular signal-regulated kinase activation. Interestingly, analysis of TGF-β receptor expression showed a decrease in both receptor I and II expression in TGF-β1 silenced cells. These results suggest that inhibition of TGF-β1 ligand may act as a negative feedback loop to disrupt the function of all TGF-β isoforms.

Conclusions: Therapies targeting the TGF-β signaling pathway may be more effective in late-stage disease to prevent organ metastasis but not primary tumor formation and may be combined with other tumor-targeted therapies normally limited by increased circulating TGF-β levels.
Data from Identification of the Molecular Mechanisms for Dedifferentiation at the Invasion Front of Colorectal Cancer by a Gene Expression Analysis
Authors: Oku Yoshimasa , Shimoji Takashi , Takifuji Katsunari , Hotta Tsukasa , Yokoyama Shozo , Matsuda Kenji , Higashiguchi Takashi , Tominaga Toshiji , Nasu Toru , Tamura Koichi , Matsuura Masaaki , Miyata Satoshi , Kato Yo , Yamaue Hiroki , Miki Yoshio
Published: April 2023

Abstract
Purpose: The aim of this study is to identify gene expression signatures that accompany dedifferentiation at the cancer invasion front in colorectal cancer.

Experimental Design: Two types of colorectal cancer were selected. Both types were well-differentiated adenocarcinomas at the superficial lesion. One type showed a dedifferentiated phenotype at the invasion front (type A, 13 samples); the other showed almost no dedifferentiated cancer cells at the invasion front (type B, 12 samples). Laser microdissection was combined with a cDNA microarray analysis to investigate the superficial lesions and the invasion front in colorectal cancers.

Results: Eighty-three genes were differentially expressed between types A and B in the superficial lesions, and the samples of superficial lesions were divided correctly into two clusters by these genes. Interestingly, the samples of the invasion front were also divided into the two same clusters by these genes. The text mining method selected 10 genes involved in potential mechanisms causing dedifferentiation of cancer cells at the invasion front. The potential mechanisms include the networks of transforming growth factor-β, Wnt, and Hedgehog signals. The expression levels of 10 genes were calculated by quantitative reverse transcription-PCR and 8 genes were confirmed to be significantly differentially expressed between two types (P < 0.05). The gene expression profiles of 8 genes divided 12 test cases into two clusters with one misclassification.

Conclusions: The molecular mechanisms constructed with 8 genes from three networks of transforming growth factor-β, Wnt, and Hedgehog signals were found to correlate with dedifferentiation at the invasion front of colorectal cancer.